---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-207791"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2022-08-01T23:59:59+00:00"
generated_at: "2026-06-24T06:20:01.510820+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Vaccinex presents pepinemab AD/HD data at AAIC 2022; SIGNAL-AD first patient completed with no safety concerns

## Summary
- Presented poster at AAIC 2022 on pepinemab (SEMA4D antibody) for Alzheimer's and Huntington's disease.
- Phase 2 HD study showed pepinemab restored learning and increased brain metabolic activity (FDG-PET).
- Ongoing Phase 1/2a SIGNAL-AD study: first patient completed with no safety concerns as of Q2 2022.
- Pepinemab targets glial activation to reduce neuroinflammation; funded by Alzheimer's Association and ADDF.

## SEC filing metadata
- accession: 0001193125-22-207791
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2022-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312522207791/0001193125-22-207791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312522207791/d340607d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-207791
- JSON: https://secwatch.observer/filing/0001193125-22-207791.json
- Plain text: https://secwatch.observer/filing/0001193125-22-207791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.